Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
21.26
-0.86 (-3.89%)
At close: Apr 28, 2026, 4:00 PM EDT
21.21
-0.05 (-0.23%)
After-hours: Apr 28, 2026, 7:55 PM EDT
Summit Therapeutics Stock Forecast
Stock Price Forecast
The 15 analysts with 12-month price forecasts for Summit Therapeutics stock have an average target of 32.93, with a low estimate of 12 and a high estimate of 45. The average target predicts an increase of 54.89% from the current stock price of 21.26.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Summit Therapeutics stock from 17 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 8 | 7 | 7 | 7 | 8 |
| Buy | 5 | 4 | 4 | 4 | 4 | 4 |
| Hold | 2 | 3 | 3 | 3 | 4 | 4 |
| Sell | 2 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 16 | 15 | 15 | 16 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Initiates $45 | Strong Buy | Initiates | $45 | +111.67% | Apr 8, 2026 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $42 → $15 | Strong Buy → Hold | Downgrades | $42 → $15 | -29.44% | Mar 16, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $40 → $30 | Strong Buy | Maintains | $40 → $30 | +41.11% | Feb 24, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +88.15% | Feb 2, 2026 |
| Citizens | Citizens | Buy Reiterates $40 | Buy | Reiterates | $40 | +88.15% | Jan 30, 2026 |
Financial Forecast
Revenue This Year
8.53M
Revenue Next Year
105.96M
from 8.53M
Increased by 1,142.50%
EPS This Year
-1.07
from -1.44
EPS Next Year
-1.10
from -1.07
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 61.0M | 377.9M | ||||||
| Avg | 8.5M | 106.0M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 4,330.9% | ||||||
| Avg | - | 1,142.5% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.60 | -0.61 | ||||||
| Avg | -1.07 | -1.10 | ||||||
| Low | -1.62 | -1.74 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.